Alpha 2.0
Login Register
» Authors » Benita Ukkonen

Benita Ukkonen

Explore the profile of Benita Ukkonen including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 6
Citations 72
Followers 0
Related Specialties
Infectious Diseases
General Medicine
Pediatrics
Top 10 Co-Authors
Bruce Tapiero
Joanne M Langley
Charu Sabharwal
Outi Laajalahti
Stephen Lockhart
Hua Ma
Kathrin U Jansen
Peter Silas
Nicholas Kitchin
Xuping Xie
Published In
Hum Vaccin Immunother
J Pediatric Infect Dis Soc
Clin Infect Dis
Open Forum Infect Dis
N Engl J Med
Affiliations
Soon will be listed here.
Recent Articles
1.
Breadth of immune response, immunogenicity, reactogenicity, and safety for a pentavalent meningococcal ABCWY vaccine in healthy adolescents and young adults: results from a phase 3, randomised, controlled observer-blinded trial
Nolan T, Bhusal C, Beran J, Bloch M, Cetin B, Dinleyici E, et al.
Lancet Infect Dis . 2024 Dec; PMID: 39647494
Background: A multicomponent meningococcal serogroups ABCWY vaccine (MenABCWY) could provide broad protection against disease-causing meningococcal strains and simplify the immunisation schedule. The aim of this trial was to confirm the...
2.
4CMenB Breadth of Immune Response, Immunogenicity, and Safety: Results From a Phase 3 Randomized, Controlled, Observer Blind Study in Adolescents and Young Adults
Nolan T, Bhusal C, Beran J, Bloch M, Cetin B, Dinleyici E, et al.
Open Forum Infect Dis . 2024 Nov; 11(11):ofae638. PMID: 39582508
Background: Meningococcal serogroup B (MenB) strains are highly diverse. Breadth of immune response for the MenB vaccine, 4CMenB, administered at 0-2, 0-6, or 0-2-6 months, was demonstrated by endogenous complement-human...
3.
Immunogenicity and Safety of a Third COVID-19 BNT162b2 mRNA Vaccine Dose in 5- to 11-Year Olds
Simoes E, Klein N, Sabharwal C, Gurtman A, Kitchin N, Ukkonen B, et al.
J Pediatric Infect Dis Soc . 2023 Mar; 12(4):234-238. PMID: 36929216
In this ongoing study, substantially increased ancestral SARS-CoV-2 neutralizing responses were observed 1 month after a third 10-µg BNT162b2 dose given to 5 to 11-year olds versus neutralizing responses post-dose...
4.
Evaluation of BNT162b2 Covid-19 Vaccine in Children Younger than 5 Years of Age
Munoz F, Sher L, Sabharwal C, Gurtman A, Xu X, Kitchin N, et al.
N Engl J Med . 2023 Feb; 388(7):621-634. PMID: 36791162
Background: Safe and effective vaccines against coronavirus disease 2019 (Covid-19) are urgently needed in young children. Methods: We conducted a phase 1 dose-finding study and are conducting an ongoing phase...
5.
The Adjuvanted Recombinant Zoster Vaccine Confers Long-Term Protection Against Herpes Zoster: Interim Results of an Extension Study of the Pivotal Phase 3 Clinical Trials ZOE-50 and ZOE-70
Boutry C, Hastie A, Diez-Domingo J, Tinoco J, Yu C, Andrews C, et al.
Clin Infect Dis . 2021 Jul; 74(8):1459-1467. PMID: 34283213
Background: This ongoing follow-up study evaluated the persistence of efficacy and immune responses for 6 additional years in adults vaccinated with the glycoprotein E (gE)-based adjuvanted recombinant zoster vaccine (RZV)...
6.
Immunogenicity and safety of an investigational quadrivalent meningococcal conjugate vaccine administered as a booster dose in children vaccinated against meningococcal disease 3 years earlier as toddlers: A Phase III, open-label, multi-center study
Piazza F, Virta M, Paassilta M, Ukkonen B, Ahonen A, Esteves-Jaramillo A, et al.
Hum Vaccin Immunother . 2021 Jun; 18(1):1-10. PMID: 34085900
Booster doses of meningococcal conjugate vaccines induce long-term protection against invasive meningococcal disease. We evaluated the immunogenicity and safety of a booster dose of MenACYW-TT in pre-school children who were...